3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Prostatic Neoplasms
54
Breast Neoplasms
43
Neoplasms
4
Salivary Gland Neoplasms
3
Triple Negative Breast Neoplasms
2
Prostate Adenocarcinoma
2
Advanced Breast Cancer
2
Recurrence
1
PSA Level Greater Than Two
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Lymphatic Metastasis
1
Inflammatory Breast Neoplasms
1
Hormone-sensitive Metastatic Breast Cancer
1
Hormone Sensitive Prostate Cancer
1
Hodgkin Disease
1
Hereditary Sensory and Autonomic Neuropathies
1
HER2-positive Breast Cancer
1
HER2 Negative Breast Cancer
1
Fallopian Tube Neoplasms
1
Castrate Sensitive Prostate Cancer
1
Carcinoma, Ovarian Epithelial
1
Carcinoma, Lobular
1
Bulbo-Spinal Atrophy, X-Linked
1
Breast Neoplasms, Male
1
Anatomic Stage I Breast Cancer AJCC v8
1
Interventions
Cyclophosphamide
115
fludarabine phosphate
67
Mycophenolic Acid
62
Etoposide
61
Peripheral Blood Stem Cell Transplantation
58
Tacrolimus
55
Melphalan
48
Filgrastim
48
Busulfan
48
Whole-Body Irradiation
47
Doxorubicin
46
Radiotherapy
42
fludarabine
38
Cyclosporine
38
Brentuximab Vedotin
38
Vinblastine
35
Granulocyte Colony-Stimulating Factor
35
Antilymphocyte Serum
30
Methotrexate
29
Dacarbazine
29
Gemcitabine
28
Rituximab
26
Nivolumab
25
Prednisone
24
Bleomycin
24
Vincristine
22
pembrolizumab
21
Carmustine
21
Cytarabine
20
thymoglobulin
16
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Hodgkin Disease
×
Goserelin
×
Clear all
NCT01014507
2012-06-25
PROFE
University of Cologne
Phase 2
Completed
60 enrolled